RxDoctor Payments Data

John Imhoff, MD

Ophthalmology · Brunswick, GANPI 1669480513

Payments from drug & device makers

$3,027in general payments, 2019–2025

Across 72 payments — averaging $42.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$2K
  • Rxsight Inc$674
  • Johnson & Johnson Surgical Vision, Inc.$620
  • Sight Sciences, Inc.$124
  • AbbVie$59
  • Halozyme Inc$22
  • plus $19 from 1 others

What the payments were for

  • Food & beverage$3,027100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,027 in reported general payments places this provider in the 55th percentile of 481 ophthalmology providers in Georgia.

See all ophthalmology providers in Georgia

Medicare billing

Part B allowed, 2024
$294,447
Medicare patients
403
Services billed
1,344

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Prednisolone Acetate858$38,440
LumiganBimatoprost39$14,379
Ketorolac Tromethamine495$8,917
RhopressaNetarsudil Mesylate15$6,465
Ofloxacin489$5,390
Latanoprost204$1,623
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol14$1,021
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat32$663
Dorzolamide Hcl21$445
Timolol Maleate73$398
Brimonidine Tartrate47$362
Polymyxin B Sul-TrimethoprimPolymyxin B Sulf/Trimethoprim15$131
Alprazolam13$7

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan$59$14,37939 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 481 ophthalmology providers in Georgia.

Other ophthalmology in Brunswick

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →